Does TrumpRx Deliver? Evaluating Real Savings, Market Impact, and Unresolved Legal Questions (On-Demand Webinar)

Closed captions are available. 

Overview: This 60-minute webinar provides a fact-based, non-partisan examination of TrumpRx, the Trump administration's direct-to-consumer prescription drug platform, including how it works, who it benefits, and whether it delivers meaningful savings beyond what was already available to consumers through existing discount programs. Presenters also analyze the HHS OIG's January 2026 Special Advisory Bulletin on direct-to-consumer drug sales, exploring the legal questions and notable inconsistencies the guidance leaves unresolved — including open Anti-Kickback Statute compliance questions and concerns raised by members of Congress. Drawing on perspectives from both legal and drug pricing and managed care consulting expertise, this webinar offers attendees a comprehensive and objective framework for evaluating TrumpRx and its implications for payers, plans, and the broader health care market.

Learning Objectives: 

• Learn TrumpRx works and whether it offers meaningful savings to consumers.
• Analyze the OIG's January 2026 DTC guidance, including its gaps and unresolved legal questions.
  
• Evaluate TrumpRx's implications for payers, plans, and the managed care landscape.
  

Speaker Information: 

Brian Hoyt, Managing Director, BRG 

Tiffanie McDowell, Partner, Crowell & Moring 

Shannon Wiley, Member, Bass, Berry & Sims 

Credit Information: 

CCB: CCB credits are not available for this on-demand webinar. 

For additional information, please visit the AHLA Continuing Education page.